The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial

INTRODUCTION: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have cardiovascular protective properties in addition to the metabolic effects and represent a cornerstone of treating patients with chronic heart failure (CHF). We hypothesised that empagliflozin reduces tissue sodium content in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolwelter, Julie, Kannenkeril, Dennis, Linz, Peter, Jung, Susanne, Nagel, Armin M., Bosch, Agnes, Ott, Christian, Bramlage, Peter, Nöh, Lisa, Schiffer, Mario, Uder, Michael, Achenbach, Stephan, Schmieder, Roland E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849317/
https://www.ncbi.nlm.nih.gov/pubmed/36289063
http://dx.doi.org/10.1007/s00392-022-02119-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849317/
https://www.ncbi.nlm.nih.gov/pubmed/36289063
http://dx.doi.org/10.1007/s00392-022-02119-7

Ejemplares similares